TROP2-targeted molecular imaging: a promising tool for precision oncology

Area of Science:

• Oncology
• Molecular Imaging
• Biotechnology

Background:

• Trophoblast cell surface antigen 2 (TROP2) is a promising target for antibody-drug conjugate (ADC) cancer therapies.
• TROP2 expression levels correlate with the efficacy of TROP2-ADCs, indicating its potential for patient stratification.
• Current methods like immunohistochemistry (IHC) for TROP2 detection have limitations.

Purpose of the Study:

• To review the progress of TROP2-targeted molecular imaging for cancer diagnosis and therapy.
• To discuss the potential of non-invasive imaging techniques to overcome limitations of current TROP2 detection methods.
• To explore innovative approaches for clinical translation of TROP2 molecular imaging.

Main Methods:

• Review of research on TROP2-targeted molecular imaging technologies, including immuno-Positron Emission Tomography (immunoPET).
• Exploration of various TROP2-targeting agents such as radiolabeled antibodies, nanobodies, peptides, and small molecules.
• Discussion of current technical challenges and strategies for clinical implementation.

Main Results:

• TROP2-targeted ADCs show promising efficacy in treating advanced metastatic cancers.
• Non-invasive molecular imaging, particularly immunoPET, enables feasible measurement of TROP2 expression.
• TROP2 expression serves as a predictive biomarker for therapy response.

Conclusions:

• TROP2-targeted molecular imaging is a significant advancement in precision oncology.
• Non-invasive imaging can guide treatment strategies and enhance therapeutic outcomes.
• Further innovation is needed to overcome challenges and accelerate clinical adoption of TROP2 imaging.